A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!

Am J Respir Crit Care Med · 2021 · PMC8650784 · PMID 33856964

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

This NIH-sponsored trial showed acceptable drug safety and tolerability but failed to reach significance for the primary (6-min-walk distance [6MWD] change from baseline at 24 weeks) and secondary endpoints, which included a change in pulmonary vascular resistance.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.